FDA approves gene tekolizumab in combination with chemotherapy to treat metastatic non-small cell lung cancer

today, Genentech, a member of the Roche group, announced that the UsFDA(http://approved tecentriq (atezolizumab) and chemotherapy (Abraxane (a purple sequoia protein binding; nab-purple alcohol) and cappisol) combination as a first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) without EGFR or ALK mutationsThis approval is based on the results of a clinical Phase 3 study of IMpower130, which showed that Tecentriq combined chemotherapy significantly prolonged the survival of patients compared to pure chemotherapy (18.6 months of median total survival and 13.9 months in the control group); In the wild population with intentional treatment, HR is HR 0.80; 95% CI: 0.64-0.99; p-0.0384)tecentriq-based combination therapy also significantly reduced the risk of disease deterioration or death (median PFS was 7.2 to 6.5 months; HR - 0.75; 95% CI: 0.63-0.91; p-0.0024)The safety of Tecentriq combined chemotherapy appears to be consistent with the known safety of theof a singledrug(http:// and there are no new safety signalsIn the case of lung cancer, Tecentriq has been approved for use in combination with Avastin (bevanmono), yew alcohol, and caplatinum as a first-line treatment for patients with metastatic non-small cell lung cancer without EGFR or ALK gene mutationsTecentriq was approved by the FDA to treat adult metastatic non-small cell lung cancer patients who developed disease during or after chemotherapy containing platinumPatients with mutations in the EGFR or ALK gene should receive FDA-approved treatment before receiving Tecentriq treatmentTecentriq combined caplatin and etoposide etopolyses have also been approved for first-line treatment for a wide range of advanced small cell lung cancer (ES-SCLC)